Insights into Plan Year 2027: Maximum Fair Price for Prescription Drugs

Plan Year 2027 (PY27) Maximum Fair Price (MFP) negotiations under the Inflation Reduction Act unfolded against the backdrop of Trump-era Most Favored Nation (MFN) executive orders and a volatile Part D market. Final MFPs are set, and CMS has published the methodology behind them. This webinar decodes what those prices reveal about the current administration’s drug-pricing trajectory, manufacturer margin outlook and pipeline risk, and the stability of Part D premiums and formularies. We’ll connect therapeutic-class patterns and comparator choices to likely plan behavior—tiering, utilization management (UM), and benefit-channel steering—and near-term contracting dynamics. Walk away from this CCA healthcare series webinar with a concise playbook for how PY27 MFPs will shape 2026–2028 strategy for payers and manufacturers.